Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.

摘要: PURPOSEFludarabine (2-fluoro-arabanoside-monophosphate) is a new antimetabolite chemotherapeutic agent. We performed multicenter, phase II study of this drug in previously treated patients with refractory or relapsed non-Hodgkin's lymphoma (NHL) to determine its response rate by histologic classification.PATIENTS AND METHODSSixty-two assessable were given 18 mg/m2 intravenous (IV) bolus injection daily for 5 days, every 28 days. Forty-eight percent had one chemotherapy regimen, and the remainder two regimens; 42% radiation.RESULTSPatients received 273 cycles fludarabine chemotherapy, median ranging up 25 cycles. Sixty response, including nine complete responses (CRs; 15%) partial (PRs; 15%). The lower-grade histology was 52% (13 25); greatest seen those follicular small cleaved-cell lymphoma, seven 11 treat...